The Journal of Urology
Volume 184, Issue 2 , Pages 731-737 , August 2010

Aberrant Promoter Methylation of DLEC1, a Critical 3p22 Tumor Suppressor for Renal Cell Carcinoma, is Associated With More Advanced Tumor Stage

  • Qian Zhang

      Affiliations

    • Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, China
    • National Research Center for Genitourinary Oncology, China
    • Joint Center for Cancer Epigenetics, China
    • Equal study contribution.
    • ,
  • Jianming Ying

      Affiliations

    • National Research Center for Genitourinary Oncology, China
    • Joint Center for Cancer Epigenetics, China
    • Department of Pathology, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
    • Equal study contribution.
    • ,
  • Jisheng Li

      Affiliations

    • Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
    • ,
  • Yichao Fan

      Affiliations

    • Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
    • ,
  • Fan Fong Poon

      Affiliations

    • Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
    • ,
  • Ka Man Ng

      Affiliations

    • Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
    • ,
  • Qian Tao

      Affiliations

    • National Research Center for Genitourinary Oncology, China
    • Joint Center for Cancer Epigenetics, China
    • Cancer Epigenetics Laboratory, State Key Laboratory in Oncology in South China, Sir Y. K. Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China
    • Corresponding Author InformationCorrespondence: Room 315, Cancer Center, PWH, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong, China (telephone: 852-2632-1340; FAX: 852-2648-8842)
    • ,
  • Jie Jin

      Affiliations

    • Department of Urology, Peking University First Hospital and Institute of Urology, Peking University, China
    • National Research Center for Genitourinary Oncology, China
    • Joint Center for Cancer Epigenetics, China
    • Corresponding Author InformationCorrespondence: Department of Urology, Peking University First Hospital, Beijing, China (telephone: (86) 10-66551122-2627; FAX: (86) 10-66175710)

Received 2 December 2008

References 

  1. McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin Oncol. 2006;33:527
  2. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157
  3. Sukosd F, Kuroda N, Beothe T, et al. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res. 2003;63:455
  4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415
  5. Yamada D, Kikuchi S, Williams YN, et al. Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer. 2006;118:916
  6. Morris MR, Gentle D, Abdulrahman M, et al. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res. 2005;65:4598
  7. Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21 3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A. 2001;98:7504
  8. Breault JE, Shiina H, Igawa M, et al. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin Cancer Res. 2005;11:557
  9. Okuda H, Toyota M, Ishida W, et al. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene. 2006;25:1733
  10. Sanz-Casla MT, Maestro ML, del BV, et al. Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol Res. 2003;31:159
  11. Zhang Q, Ying J, Zhang K, et al. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett. 2007;249:220
  12. Imreh S, Klein G, Zabarovsky ER. Search for unknown tumor-antagonizing genes. Genes Chromosomes Cancer. 2003;38:307
  13. Ito M, Ito G, Kondo M, et al. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21 3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett. 2005;225:131
  14. Qiu GH, Salto-Tellez M, Ross JA, et al. The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. J Hepatol. 2008;48:433
  15. Ying J, Poon FF, Yu J, et al. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer. 2009;100:663
  16. Greene FL. American Joint Committee on Cancer Staging Manual. New York: Springer-Verlag; 2002;
  17. Ying J, Srivastava G, Hsieh WS, et al. The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res. 2005;11:6442
  18. Tao Q, Huang H, Geiman TM, et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet. 2002;11:2091
  19. Kwong J, Lee JY, Wong KK, et al. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia. 2006;8:268
  20. Kwong J, Chow LS, Wong AY, et al. Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 2007;46:171
  21. Dulaimi E, Ibanez dC I Uzzo RG, et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004;10:3972
  22. Daigo Y, Nishiwaki T, Kawasoe T, et al. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21 3. Cancer Res. 1999;59:1966
  23. Blute ML, Leibovich BC, Lohse CM, et al. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int. 2004;94:33
  24. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer. 2007;7:531
  25. Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64:5511

 Study received institutional review board approval.

 Supported by NSFC Grant 30928012 and The Chinese University of Hong Kong.

PII: S0022-5347(10)03206-4

doi: 10.1016/j.juro.2010.03.108

The Journal of Urology
Volume 184, Issue 2 , Pages 731-737 , August 2010

Article Tools

* Image Usage & Resolution